Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 10/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | EP300 | Q09472 | 2/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22482203 | 0.86 | CDK5 (0.44) | RBP4CDK5CDK5R1NAMPTGAA | |
| SCHEMBL17870544 | 0.84 | RBP4 (0.40) | RBP4CDK5CDK5R1NAMPTEP300 | |
| SCHEMBL29386147 | 0.83 | RBP4 (0.42) | RBP4NAMPTEP300CREBBPGAA | |
| SCHEMBL5465401 | 0.83 | KDM4E (0.47) | RBP4CDK5CDK5R1GSK3BNAMPT | |
| SCHEMBL4795587 | 0.81 | NPC1 (0.48) | RBP4CDK5CDK5R1GAANPC1 | |
| SCHEMBL22481978 | 0.80 | HSP90AA1 (0.45) | GAANPC1RAB9A | |
| SCHEMBL22482230 | 0.80 | ADORA1 (0.39) | GSK3BDYRK1A | |
| SCHEMBL22029668 | 0.80 | NAMPT (0.36) | RBP4CDK5CDK5R1NAMPTEP300 | |
| SCHEMBL4792110 | 0.79 | ADORA1 (0.46) | RBP4EP300CREBBPBRD4 | |
| SCHEMBL14520683 | 0.79 | ESR2 (0.41) | RBP4EP300CREBBPBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119419-A1 | BYCYCLIC JAK INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (HK) | 2022-04-21 | — | — | US | disclosed |
| WO-2020198583-A1 | BICYCLIC JAK INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2020-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119419-A1 | BYCYCLIC JAK INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | RBP4 3072/4885CDK5 27/4885CDK5R1 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.